Available treatment options for dystonia

被引:4
|
作者
Alfradique-Dunham, Isabel
Jankovic, Joseph [1 ,2 ]
机构
[1] Baylor Coll Med, Parkinsons Dis Ctr, 7200 Cambridge,Suite 9A, Houston, TX 77030 USA
[2] Baylor Coll Med, Dept Neurol, Movement Disorders Clin, 7200 Cambridge,Suite 9A, Houston, TX 77030 USA
来源
EXPERT OPINION ON ORPHAN DRUGS | 2017年 / 5卷 / 09期
基金
美国国家卫生研究院;
关键词
Dystonia; botulinum toxin; deep brain stimulation; DEEP-BRAIN-STIMULATION; HYPERKINETIC MOVEMENT-DISORDERS; TOXIN TYPE-B; PLACEBO-CONTROLLED TRIAL; BENIGN ESSENTIAL BLEPHAROSPASM; PRIMARY GENERALIZED DYSTONIA; INCOBOTULINUMTOXINA NT 201; DOUBLE-BLIND CROSSOVER; BOTULINUM-TOXIN; CERVICAL DYSTONIA;
D O I
10.1080/21678707.2017.1366309
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Dystonia is a neurologic movement disorder characterized by sustained or intermittent muscle contractions causing abnormal, often repetitive, movements, postures, or both. The etiology of dystonia is diverse and it includes genetic and other causes. Since the advent of botulinum toxin and deep brain stimulation, the treatment of dystonia has markedly improved and is still evolving. Areas covered: This review gives a historical overview of the treatment options for dystonia. In the absence of pathogenesis-targeted, disease-modifying therapies, the treatment of dystonia remains symptomatic. Botulinum toxin is the first line treatment for some forms of focal and segmental dystonias. Oral medications, including anticholinergics, baclofen, benzodiazepines and antidopaminergic drugs are used primarily in patients with generalized dystonia. Levodopa is an effective treatment for patients with dopa-responsive-dystonia. The use of deep brain stimulation, intrathecal and intraventricular baclofen, as well as ablative surgeries are options for patients with disabling dystonia refractory to other, less invasive, therapies. Expert opinion: The selected treatment modality should be tailored to the patient's needs and guided by potential side effects. Refractory cases should be referred to tertiary center for evaluation with a multidisciplinary team and potential surgical treatment.
引用
收藏
页码:707 / 716
页数:10
相关论文
共 50 条
  • [41] Pain Management in Multiple Sclerosis: a Review of Available Treatment Options
    Talal Aboud
    Nathaniel M. Schuster
    Current Treatment Options in Neurology, 2019, 21
  • [42] Hepatitis B in HIV: Available treatment options and approach to therapy
    Osborn M.
    Current Infectious Disease Reports, 2009, 11 (5) : 407 - 413
  • [43] How to select amongst available options for the treatment of advanced RCC?
    Escudier, B.
    Albiges, L.
    Massard, C.
    Loriot, Y.
    Fizazi, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 309 - 312
  • [44] Pharmacological Treatment of Enthesitis - A Systematic Review on the Efficacy of the Available Options
    Torres, Rita
    Manica, Santiago
    Santos, Fernando
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3823 - 3825
  • [45] Current Treatment Options Available for COVID-19: A Review
    Mehta, Maulin
    Patharkar, Jayant
    ASIAN JOURNAL OF PHARMACEUTICAL RESEARCH AND HEALTH CARE, 2020, 12 (03) : 141 - 147
  • [46] Coccydynia-The Efficacy of Available Treatment Options: A Systematic Review
    Anderson, Gustav O.
    Milosevic, Stefan
    Jensen, Mads M.
    Anderson, Mikkel O.
    Simony, Ane
    Rasmussen, Mikkel M.
    Carreon, Leah
    GLOBAL SPINE JOURNAL, 2022, 12 (07) : 1611 - 1623
  • [47] Treatment of severe, refractory vasculitis: Rational use of available options
    Gross, WL
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 2 - 2
  • [48] THE OPTIONS AVAILABLE FOR AMMONIA REMOVAL AT DAVYHULME SEWAGE-TREATMENT WORKS
    DOLAN, JF
    ONEILL, MJ
    HORAN, NJ
    JOURNAL OF THE INSTITUTION OF WATER AND ENVIRONMENTAL MANAGEMENT, 1990, 4 (05): : 457 - 468
  • [49] Spontaneous coronary artery dissection: a review of the etiology and available treatment options
    Andrew B. McCann
    Robert J. Whitbourn
    Heart and Vessels, 2009, 24 : 463 - 465
  • [50] Managing comorbid anxiety with depression using currently available treatment options
    Roy-Byrne, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2006, 16 : S574 - S575